Apart from dysregulation at the receptor level, activating mutations or overexpression of the Gα12, Gα13 and RhoA downstream signaling components were shown to be risk factors in prostate cancer [153,154,155]. This evidence concerns the gene RHOA and Familial prostate cancer.